ERAS (Erasca) Other Current Liabilities: $6.55 Mil (As of Mar. 2026)


ERAS Erasca Inc ERAS
22 GF Score
Price $17.84
! 2 Warning Signs
View Full Analysis

What is Erasca Other Current Liabilities?

Erasca ERAS -2.46% 22 Other Current Liabilities is $6.55 Mil as of Mar. 2026. GuruFocus rates ERAS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Erasca's other current liabilities for the quarter that ended in Mar. 2026 was $6.55 Mil.

Erasca's quarterly other current liabilities increased from Sep. 2025 ($8.94 Mil) to Dec. 2025 ($12.07 Mil) but then declined from Dec. 2025 ($12.07 Mil) to Mar. 2026 ($6.55 Mil).

Erasca's annual other current liabilities declined from Dec. 2023 ($10.78 Mil) to Dec. 2024 ($10.65 Mil) but then increased from Dec. 2024 ($10.65 Mil) to Dec. 2025 ($12.07 Mil).

Erasca Other Current Liabilities Related Terms

Erasca Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Erasca's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Erasca Other Current Liabilities Chart

Erasca Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 10.16 11.09 10.78 10.65 12.07

Erasca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.81 6.64 8.94 12.07 6.55
ERAS
22GF Score
Erasca Inc ERAS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Erasca Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $6.55 Mil mean?
Erasca (ERAS) has a Other Current Liabilities of $6.55 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Erasca.
Is Erasca's Other Current Liabilities too high?
Erasca's current Other Current Liabilities is $6.55 Mil. Overall, Erasca has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Erasca's Other Current Liabilities compare to CELC and TNGX?
Erasca's Other Current Liabilities of $6.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Erasca. Erasca's current Other Current Liabilities is $6.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erasca stock overvalued right now?
Erasca (ERAS) has a current Other Current Liabilities of $6.55 Mil. The current Other Current Liabilities is $6.55 Mil. Erasca's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Erasca (ERAS), the current Other Current Liabilities is $6.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Erasca Business Description

Address 3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
22GF Score

Get the complete analysis for ERAS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.84
Price